125 related articles for article (PubMed ID: 16627301)
1. Abstinence-orientated buprenorphine replacement therapy for young adults in out-patient counselling.
Kornør H; Waal H; Ali RL
Drug Alcohol Rev; 2006 Mar; 25(2):123-30. PubMed ID: 16627301
[TBL] [Abstract][Full Text] [Related]
2. Time-limited buprenorphine replacement therapy for opioid dependence: 2-year follow-up outcomes in relation to programme completion and current agonist therapy status.
Kornør H; Waal H; Sandvik L
Drug Alcohol Rev; 2007 Mar; 26(2):135-41. PubMed ID: 17364848
[TBL] [Abstract][Full Text] [Related]
3. Treatment completion on an inpatient detoxification unit: impact of a change to sublingual buprenorphine-naloxone.
Soeffing JM; Rastegar DA
J Subst Abuse Treat; 2007 Dec; 33(4):401-4. PubMed ID: 17400414
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of an injection depot formulation of buprenorphine: placebo comparison.
Sigmon SC; Wong CJ; Chausmer AL; Liebson IA; Bigelow GE
Addiction; 2004 Nov; 99(11):1439-49. PubMed ID: 15500597
[TBL] [Abstract][Full Text] [Related]
5. Comparison of high dose buprenorphine treatments of opiate dependent outpatients in four healthcare networks.
De Ducla M; Gagnon A; Mucchielli A; Robinet S; Vellay A
Ann Med Interne (Paris); 2000 Oct; 151 Suppl B():B9-15. PubMed ID: 11104938
[TBL] [Abstract][Full Text] [Related]
6. Less pain, more gain: buprenorphine-naloxone and patient retention in treatment.
Renzelli CM; Capretto NA
J Addict Dis; 2006; 25(3):97-104. PubMed ID: 16956874
[TBL] [Abstract][Full Text] [Related]
7. Opioid detoxification using high doses of buprenorphine in 24 hours: a randomized, double blind, controlled clinical trial.
Assadi SM; Hafezi M; Mokri A; Razzaghi EM; Ghaeli P
J Subst Abuse Treat; 2004 Jul; 27(1):75-82. PubMed ID: 15223097
[TBL] [Abstract][Full Text] [Related]
8. Comparison of buprenorphine and methadone in the treatment of opiate withdrawal: possible advantages of buprenorphine for the treatment of opiate-benzodiazepine codependent patients?
Reed LJ; Glasper A; de Wet CJ; Bearn J; Gossop M
J Clin Psychopharmacol; 2007 Apr; 27(2):188-92. PubMed ID: 17414244
[TBL] [Abstract][Full Text] [Related]
9. Buprenorphine replacement therapy for adolescents with opioid dependence: early experience from a children's hospital-based outpatient treatment program.
Levy S; Vaughan BL; Angulo M; Knight JR
J Adolesc Health; 2007 May; 40(5):477-82. PubMed ID: 17448411
[TBL] [Abstract][Full Text] [Related]
10. Retention and attendance with supervised buprenorphine treatment: a case-note review.
Bell J; Burrell T
Drug Alcohol Rev; 2006 Mar; 25(2):161-5. PubMed ID: 16627306
[TBL] [Abstract][Full Text] [Related]
11. Inpatient initiation of buprenorphine maintenance vs. detoxification: can retention of opioid-dependent patients in outpatient counseling be improved?
Caldiero RM; Parran TV; Adelman CL; Piche B
Am J Addict; 2006; 15(1):1-7. PubMed ID: 16449087
[TBL] [Abstract][Full Text] [Related]
12. Optimising the benefits of unobserved dose administration for stable opioid maintenance patients: follow-up of a randomised trial.
Bell JR; Ryan A; Mutch C; Batey R; Rea F
Drug Alcohol Depend; 2008 Jul; 96(1-2):183-6. PubMed ID: 18423901
[TBL] [Abstract][Full Text] [Related]
13. Treatment retention in adolescent patients treated with methadone or buprenorphine for opioid dependence: a file review.
Bell J; Mutch C
Drug Alcohol Rev; 2006 Mar; 25(2):167-71. PubMed ID: 16627307
[TBL] [Abstract][Full Text] [Related]
14. A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence.
Petry NM; Bickel WK; Badger GJ
Clin Pharmacol Ther; 1999 Sep; 66(3):306-14. PubMed ID: 10511067
[TBL] [Abstract][Full Text] [Related]
15. Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing.
Marsch LA; Bickel WK; Badger GJ; Jacobs EA
Drug Alcohol Depend; 2005 Feb; 77(2):195-204. PubMed ID: 15664721
[TBL] [Abstract][Full Text] [Related]
16. A comparison of buprenorphine and lofexidine for community opiate detoxification: results from a randomized controlled trial.
Raistrick D; West D; Finnegan O; Thistlethwaite G; Brearley R; Banbery J
Addiction; 2005 Dec; 100(12):1860-7. PubMed ID: 16367987
[TBL] [Abstract][Full Text] [Related]
17. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved.
Degenhardt L; Randall D; Hall W; Law M; Butler T; Burns L
Drug Alcohol Depend; 2009 Nov; 105(1-2):9-15. PubMed ID: 19608355
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic response in outpatient opioid substitution treatment].
Barisić V; Barisić Z
Acta Med Croatica; 2009 Oct; 63(4):279-83. PubMed ID: 20034328
[TBL] [Abstract][Full Text] [Related]
19. Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine.
Reece AS
J Subst Abuse Treat; 2009 Oct; 37(3):256-65. PubMed ID: 19394789
[TBL] [Abstract][Full Text] [Related]
20. From opioid maintenance to abstinence: a literature review.
Kornør H; Waal H
Drug Alcohol Rev; 2005 May; 24(3):267-74. PubMed ID: 16096130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
